Stock 688238 OBIO TECHNOLOGY (SHANGHAI) CORP., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Obio Technology (Shanghai) Corp., Ltd.

Equities

688238

CNE1000059N9

End-of-day quote Shanghai S.E.
Other stock markets
 18:00:00 2024-06-06 EDT 		5-day change 1st Jan Change
5.05 CNY +2.64% Intraday chart for Obio Technology (Shanghai) Corp., Ltd. -10.62% -43.83%
05-30 OBiO Technology Officially Launches the Center for Clinical Evaluation and Translation of Advanced Therapies for Pediatric Rare and Genetic Diseases CI
05-16 Obio Technology's Shareholders to Offload Up to 1.5% Stake MT

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • The opinion of analysts covering the stock has improved over the past four months.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company has insufficient levels of profitability.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
OBIO TECHNOLOGY (SHANGHAI) CORP., LTD. Stock Obio Technology (Shanghai) Corp., Ltd.
-43.83% 451M -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+45.82% 765B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+40.95% 632B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.16% 354B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.86% 331B
B-
ABBVIE INC. Stock AbbVie Inc.
+9.32% 299B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+18.45% 248B
B+
ROCHE HOLDING AG Stock Roche Holding AG
-0.78% 219B
A+
NOVARTIS AG Stock Novartis AG
+11.88% 216B
B-
AMGEN INC. Stock Amgen Inc.
+5.90% 164B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 688238 Stock
  4. Ratings Obio Technology (Shanghai) Corp., Ltd.